Skip to content

Incyte INCY Price / earnings

Price / earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
17×-6.2×
Pfizer logo
PfizerPFE
14.7×
Gilead Sciences logo
Gilead SciencesGILD
18.8×-4.6×
Johnson & Johnson logo
Johnson & JohnsonJNJ
28×+9.7×
Amgen logo
AmgenAMGN
24.3×-3.9×
Biogen logo
BiogenBIIB
18.9×+5.4×

Other financials

Income statement

See full
Revenue$1.3B+20.9%
Gross profit$1.2B+19.2%
Operating income$301.1M+46.8%
Net income$303.3M+91.7%
EPS (diluted)$1.47+83.8%

Balance sheet

See full
Cash & equivalents$3.5B+78.2%
Total debt$39.4M-8.6%
Total equity$5.6B+53.3%
Total assets$7.3B+27.7%

Cash flow

See full
Operating cash flow$369.4M+38.8%
CapEx$1.6M-43.5%
Free cash flow$367.7M+39.7%

Valuation

See full
Market cap$19.78B+59.9%
Enterprise value$16.35B+55.9%
P/S3.7×+0.9×

Profitability

See full
Gross margin92.5%-0.2pp
Operating margin30%+26.1pp
Net margin26.7%+26.2pp

Returns & leverage

See full
Return on equity30.8%+30.4pp
Debt / equity0.0×
Current ratio3.7×+1.6×

Where this comes from

Calculated from Incyte’s reported figures.

Based on the most recent quarter.

The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Incyte's price / earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Incyte's price / earnings?
Incyte (INCY) reported price / earnings of 13.1× in Q1 2026.
How has Incyte's price / earnings changed year-over-year?
Incyte's price / earnings decreased by 97.6% year-over-year, from 550.9× to 13.1×.
What is the long-term trend for Incyte's price / earnings?
Over 4 years (2021 to 2025), Incyte's price / earnings has grown at a 44.1% compound annual growth rate (CAGR), from 138.1× to 595.3×.
What does price / earnings mean?
How many dollars investors pay for each dollar of the company's annual profit.
How do you interpret price / earnings?
Lower can mean cheaper — or that the market expects earnings to fall. High multiples embed growth expectations. Meaningless when earnings are negative, so it is suppressed there.
How does price / earnings compare across companies?
Compare against the company's own history and sector peers, not across sectors with different growth and risk profiles.